News

This morning, the Regional Minister for Economic and Business Development, Mikel Irujo, presented the Navarra Health Cluster, seeking to position the region as a European benchmark in personalized medicine, one of the priorities of the S4 Smart Specialisation Strategy. The initiative, which stems from the sector's demand and is led by a driving group, is now open to other companies and entities interested in participating.

3P Biopharmaceuticals (3P), a leading contract development and manufacturing organization (CDMO) specializing in process development and cGMP manufacturing of biological products, recently awarded the best Final Project Degree (FPD) of Pharmacy. The award forms part of an agreement between 3P and the Faculty of Pharmacy at the University of Navarra promoting digital transformation and professional training within the pharmaceutical industry.

The donation is an employee initiative and is supported by the company.

Navarra advances in the Comprehensive Strategy for Personalized Medicine with the constitution of the body that will coordinate its execution.

3P Biopharmaceuticals appoints Ricardo Izquierdo as Quality Director, leading quality control, quality assurance and analytical departments

Osivax's novel oligoDOM® technology, designed to induce potent T-cell responses, will serve as the basis for this broad-spectrum vaccine against COVID-19

Elena Erroba, Director of Business Development, Communication and Marketing at 3P Biopharmaceuticals, has been elected as Navarra’s Businesswoman of the Year 2021

The investments will enable the company to increase its mammalian cell-based protein production capacity tenfold and increase its microbial cell-based protein production capacity by 50%. The total floor space of the company will triple.

3P Biopharmaceuticals incorporates a new member to the executive management team by engaging Diego Bochoeyer as Director of Strategic Development and Supply Chain.